Role of TLR2-dependent inflammation in metastatic progression

Annals of the New York Academy of Sciences

Volumn 1217, Issue 1, 2011, Pages 191-206

  Kim, Sunhwa ^a,b   Karin, Michael ^a  

^a San Diego   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Inflammation; Metastasis; TNF ; Toll like receptor; Tumor progression

Indexed keywords

CHEMOKINE; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL ACTIVATION; HUMAN; INFLAMMATION; MACROPHAGE; METASTASIS; NONHUMAN; PATHOPHYSIOLOGY; TUMOR GROWTH; TUMOR PROMOTION;

EID: 79251586865     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05882.x     Document Type: Article

References (172)

1. Balkwill, F. & L.M. Coussens 2004. Cancer: an inflammatory link. Nature 431: 405-406.
2. Balkwill, F. & A. Mantovani 2001. Inflammation and cancer: back to Virchow? Lancet 357: 539-545.
3. Coussens, L.M. & Z. Werb 2002. Inflammation and cancer. Nature 420: 860-867.
4. Karin, M. 2005. Inflammation and cancer: the long reach of Ras. Nat. Med. 11: 20-21.
5. Karin, M. 2006. Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
6. Mantovani, A., P. Allavena, A. Sica & F. Balkwill 2008. Cancer-related inflammation. Nature 454: 436-444.
7. Park, J.S., D. Svetkauskaite, Q. He, et al 2004. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279: 7370-7377.
8. Sakurai, T., G. He, A. Matsuzawa, et al 2008. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14: 156-165.
9. Kawai, T. & S. Akira The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11: 373-384.
10. O'Neill, L.A. 2008. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity 29: 12-20.
11. Saikumar, P., Z. Dong, V. Mikhailov, et al 1999. Apoptosis: definition, mechanisms, and relevance to disease. Am. J. Med. 107: 489-506.
12. Vanlangenakker, N., T. Vanden Berghe, D.V. Krysko, et al 2008. Molecular mechanisms and pathophysiology of necrotic cell death. Curr. Mol. Med. 8: 207-220.
13. Lotze, M.T., H.J. Zeh, A. Rubartelli, et al 2007. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol. Rev. 220: 60-81.
14. Ellerman, J.E., C.K. Brown, M. de Vera, et al 2007. Masquerader: high mobility group box-1 and cancer. Clin. Cancer Res. 13: 2836-2848.
15. Klein, J.R., D.S. Hoon, J. Nangauyan, et al 1989. S-100 protein stimulates cellular proliferation. Cancer Immunol. Immunother. 29: 133-138.
16. Tsan, M.F. & B. Gao 2004. Cytokine function of heat shock proteins. Am. J. Physiol. Cell. Physiol. 286: C739-C744.
17. Wallin, R.P., A. Lundqvist, S.H. More, et al 2002. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 23: 130-135.
18. Zhao, Y., K. Yokota, K. Ayada, et al 2007. Helicobacter pylori heat-shock protein 60 induces interleukin-8 via a Toll-like receptor (TLR)2 and mitogen-activated protein (MAP) kinase pathway in human monocytes. J. Med. Microbiol. 56: 154-164.
19. Kalogeraki, A., F. Garbagnati, K. Darivianaki, et al 2006. HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes. Anticancer Res. 26: 3551-3554.
20. Tetu, B., B. Lacasse, H.L. Bouchard, et al 1992. Prognostic influence of HSP-27 expression in malignant fibrous histiocytoma: a clinicopathological and immunohistochemical study. Cancer Res. 52: 2325-2328.
21. Smiley, S.T., J.A. King & W.W. Hancock 2001. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J. Immunol. 167: 2887-2894.
22. Guillot, L., V. Balloy, F.X. McCormack, et al 2002. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J. Immunol. 168: 5989-5992.
23. Okamura, Y., M. Watari, E.S. Jerud, et al 2001. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem. 276: 10229-10233.
24. Saito, S., N. Yamaji, K. Yasunaga, et al 1999. The fibronectin extra domain A activates matrix metalloproteinase gene expression by an interleukin-1-dependent mechanism. J. Biol. Chem. 274: 30756-30763.
25. Johnson, G.B., G.J. Brunn, Y. Kodaira & J.L. Platt 2002. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J. Immunol. 168: 5233-5239.
26. Termeer, C., F. Benedix, J. Sleeman, et al 2002. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J. Exp. Med. 195: 99-111.
27. Biragyn, A., P.A. Ruffini, C.A. Leifer, et al 2002. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298: 1025-1029.
28. Wakasugi, K. & P. Schimmel 1999. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 284: 147-151.
29. Kim, S., H. Takahashi, W.W. Lin, et al 2009. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457: 102-106.
30. Wight, T.N. 2002. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr. Opin. Cell. Biol. 14: 617-623.
31. Adams, S., D.W. O'Neill, D. Nonaka, et al 2008. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181: 776-784.
32. Gal, S., C. Fidler, Y.M. Lo, et al 2004. Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br. J. Cancer 90: 1211-1215.
33. Wang, B.G., H.Y. Huang, Y.C. Chen, et al 2003. Increased plasma DNA integrity in cancer patients. Cancer Res. 63: 3966-3968.
34. Campana, L., L. Bosurgi & Rovere-Querini, P. 2008. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr. Opin. Immunol. 20: 518-523.
35. Kuper, H., H.O. Adami & Trichopoulos, D. 2000. Infections as a major preventable cause of human cancer. J. Intern. Med. 248: 171-183.
36. Niwa, T., T. Tsukamoto, T. Toyoda, et al 2010. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res. 70: 1430-1440.
37. Kumagai, Y., O. Takeuchi & S. Akira 2008. Pathogen recognition by innate receptors. J. Infect. Chemother. 14: 86-92.
38. Medzhitov, R., P. Preston-Hurlburt & C.A. Janeway, Jr. 1997. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397.
39. Takeda, K., T. Kaisho & S. Akira 2003. Toll-like receptors. Annu. Rev. Immunol. 21: 335-376.
40. Takeda, K. & S. Akira 2007. Toll-like receptors. Curr. Protoc. Immunol. Chapter 14, Unit 14 12.
41. Asea, A., M. Rehli, E. Kabingu, et al 2002. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J. Biol. Chem. 277: 15028-15034.
42. Kariko, K., H. Ni, J. Capodici, et al 2004. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 279: 12542-12550.
43. Ohashi, K., V. Burkart, S. Flohe & H. Kolb 2000. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J. Immunol. 164: 558-561.
44. Takeuchi, O., S. Sato, T. Horiuchi, et al 2002. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169: 10-14.
45. Takeuchi, O., K. Hoshino, T. Kawai, et al 1999. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11: 443-451.
46. Alexopoulou, L., A.C. Holt, R. Medzhitov & R.A. Flavell 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
47. Hayashi, F., K.D. Smith, A. Ozinsky, et al 2001. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410: 1099-1103.
48. Takeuchi, O., T. Kawai, P.F. Muhlradt, et al 2001. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol 13: 933-940.
49. Lund, J.M., L. Alexopoulou, A. Sato, et al 2004. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 101: 5598-5603.
50. Hemmi, H., O. Takeuchi, T. Kawai, et al 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
51. Akira, S. & K. Takeda 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4: 499-511.
52. Kopp, E. & R. Medzhitov 2003. Recognition of microbial infection by Toll-like receptors. Curr. Opin. Immunol. 15: 396-401.
53. Zhang, J.J., H.S. Wu, L. Wang, et al 2010. Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. World J. Gastroenterol. 16: 2881-2888.
54. Wang, E.L., Z.R. Qian, M. Nakasono, et al 2010. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br. J. Cancer 102: 908-915.
55. Hanahan, D. & R.A. Weinberg 2000. The hallmarks of cancer. Cell 100: 57-70.
56. Hussain, S.P., L.J. Hofseth & C.C. Harris 2003. Radical causes of cancer. Nat. Rev. Cancer 3: 276-285.
57. Jaiswal, M., N.F. LaRusso, L.J. Burgart & G.J. Gores 2000. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 60: 184-190.
58. Jaiswal, M., N.F. LaRusso & G.J. Gores 2001. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am. J. Physiol. Gastrointest. Liver. Physiol. 281: G626-G634.
59. Greten, F.R. & M. Karin 2004. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 206: 193-199.
60. Meira, L.B., J.M. Bugni, S.L. Green, et al 2008. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J. Clin. Invest. 118: 2516-2525.
61. Boudreau, J.E., B.W. Bridle, K.B. Stephenson, et al 2009. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol. Ther. 17: 1465-1472.
62. Lin, W.W. & M. Karin 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117: 1175-1183.
63. Grivennikov, S.I., F.R. Greten & M. Karin Immunity, inflammation, and cancer. Cell 140: 883-899.
64. Sparmann, A. & D. Bar-Sagi 2004. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6: 447-458.
65. Lin, E.Y., A.V. Nguyen, R.G. Russell & J.W. Pollard 2001. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193: 727-740.
66. Balkwill, F., K.A. Charles & A. Mantovani 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217.
67. Bui, J.D. & R.D. Schreiber 2007. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol 19: 203-208.
68. Karin, M., Y. Cao, F.R. Greten & Z.W. Li 2002. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2: 301-310.
69. Old, L.J. 1988. Tumor necrosis factor. Sci. Am. 258: 59-60, 69-75.
70. Arnott, C.H., K.A. Scott, R.J. Moore, et al 2002. Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene 21: 4728-4738.
71. Luo, J.L., S. Maeda, L.C. Hsu, et al 2004. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6: 297-305.
72. Grivennikov, S. & M. Karin 2008. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13: 7-9.
73. Hofseth, L.J. 2008. Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer. Cancer Lett. 268: 10-30.
74. Sawa, T. & H. Ohshima 2006. Nitrative DNA damage in inflammation and its possible role in carcinogenesis. Nitric Oxide 14: 91-100.
75. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3: 23-35.
76. Mantovani, A., A. Sica & M. Locati 2005. Macrophage polarization comes of age. Immunity 23: 344-346.
77. Mantovani, A., A. Sica, S. Sozzani, et al 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25: 677-686.
78. Kuroda, E., V. Ho, J. Ruschmann, et al 2009. SHIP represses the generation of IL-3-induced M2 macrophages by inhibiting IL-4 production from basophils. J. Immunol. 183: 3652-3660.
79. Verreck, F.A., T. de Boer, D.M. Langenberg, et al 2004. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc. Natl. Acad. Sci. USA 101: 4560-4565.
80. Mantovani, A., B. Bottazzi, F. Colotta, et al 1992. The origin and function of tumor-associated macrophages. Immunol. Today. 13: 265-270.
81. Mantovani, A., S. Sozzani, M. Locati, et al 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23: 549-555.
82. Pollard, J.W. 2004. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4: 71-78.
83. Li, H., Y. Han, Q. Guo, et al 2009. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 182: 240-249.
84. Rodriguez, P.C. & A.C. Ochoa 2008. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222: 180-191.
85. Zou, W., V. Machelon, A. Coulomb-L'Hermin, et al 2001. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7: 1339-1346.
86. Kundu, S.D., C. Lee, B.K. Billips, et al 2008. The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate 68: 223-229.
87. Li, H., X. Fan & J. Houghton 2007. Tumor microenvironment: the role of the tumor stroma in cancer. J. Cell. Biochem. 101: 805-815.
88. Haviv, I., K. Polyak, W. Qiu, et al 2009. Origin of carcinoma associated fibroblasts. Cell Cycle 8: 589-595.
89. Bhowmick, N.A., A. Chytil, D. Plieth, et al 2004. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851.
90. Tetu, B., D. Trudel & C.S. Wang 2006. [Proteases by reactive stromal cells in cancer: an attractive therapeutic target]. Bull. Cancer 93: 944-948.
91. Mueller, L., F.A. Goumas, M. Affeldt, et al 2007. Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. Am. J. Pathol. 171: 1608-1618.
92. Luo, J.L., W. Tan, J.M. Ricono, et al 2007. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446: 690-694.
93. Sasaki, A., K. Ishikawa, N. Haraguchi, et al 2007. Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis. Ann. Surg. Oncol. 14: 1191-1199.
94. Yu, H., M. Kortylewski & D. Pardoll 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7: 41-51.
95. Scortegagna, M., C. Cataisson, R.J. Martin, et al 2008. HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. Blood 111: 3343-3354.
96. Rius, J., M. Guma, C. Schachtrup, et al 2008. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453: 807-811.
97. Zinkernagel, A.S., R.S. Johnson & V. Nizet 2007. Hypoxia inducible factor (HIF) function in innate immunity and infection. J. Mol. Med. 85: 1339-1346.
98. Rossi, D. & A. Zlotnik 2000. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18: 217-242.
99. Mantovani, A., M. Muzio, C. Garlanda, et al 2001. Macrophage control of inflammation: negative pathways of regulation of inflammatory cytokines. Novartis Found Symp. 234: 120-131.
100. Norgauer, J., B. Metzner & I. Schraufstatter 1996. Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. J. Immunol. 156: 1132-1337.
101. Ottaiano, A., R. Franco, A. Aiello Talamanca, et al 2006. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin. Cancer Res. 12: 2795-2803.
102. Richmond, A. & H.G. Thomas 1986. Purification of melanoma growth stimulatory activity. J. Cell. Physiol. 129: 375-384.
103. Balkwill, F. 2002. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 13: 135-141.
104. Havell, E.A., W. Fiers & R.J. North 1988. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J. Exp. Med. 167: 1067-1085.
105. Arnott, C.H., K.A. Scott, R.J. Moore, et al 2004. Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 23: 1902-1910.
106. Knight, B., G.C. Yeoh, K.L. Husk, et al 2000. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J. Exp. Med. 192: 1809-1818.
107. Pikarsky, E., R.M. Porat, I. Stein, et al 2004. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466.
108. Greten, F.R., L. Eckmann, T.F. Greten, et al 2004. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296.
109. Galban, S., J. Fan, J.L. Martindale, et al 2003. von Hippel-Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arrays. Mol. Cell. Biol. 23: 2316-2328.
110. Tracey, K.J., S.F. Lowry, B. Beutler, et al 1986. Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. J. Exp. Med. 164: 1368-1373.
111. Onizawa, M., T. Nagaishi, T. Kanai, et al 2009. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am. J. Physiol. Gastrointest. Liver. Physiol. 296: G850-G859.
112. Anasagasti, M.J., E. Olaso, F. Calvo, et al 1997. Interleukin 1-dependent and -independent mouse melanoma metastases. J. Natl. Cancer. Inst. 89: 645-651.
113. Apte, R.N. & E. Voronov 2002. Interleukin-1-a major pleiotropic cytokine in tumor-host interactions. Semin. Cancer. Biol. 12: 277-290.
114. Song, X., E. Voronov, T. Dvorkin, et al 2003. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J. Immunol. 171: 6448-6456.
115. Dinarello, C.A. & R. Schindler 1990. Dissociation of transcription from translation of human IL-1-beta: the induction of steady state mRNA by adherence or recombinant C5a in the absence of translation. Prog. Clin. Biol. Res. 349: 195-204.
116. Greten, F.R., M.C. Arkan, J. Bollrath, et al 2007. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130: 918-931.
117. Chen, C.J., H. Kono, D. Golenbock, et al 2007. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13: 851-856.
118. Harris, T.B., L. Ferrucci, R.P. Tracy, et al 1999. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med. 106: 506-512.
119. Kiecolt-Glaser, J.K., K.J. Preacher, R.C. MacCallum, et al 2003. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc. Natl. Acad. Sci. USA 100: 9090-9095.
120. Gallucci, M., G.P. Amici, F. Ongaro, et al 2007. Associations of the plasma interleukin 6 (IL-6) levels with disability and mortality in the elderly in the Treviso Longeva (Trelong) study. Arch. Gerontol. Geriatr. 44(Suppl 1): 193-198.
121. Ershler, W.B. & E.T. Keller 2000. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu. Rev. Med. 51: 245-270.
122. Trikha, M., R. Corringham, B. Klein & J.F. Rossi 2003. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer. Res. 9: 4653-4665.
123. Honemann, D., M. Chatterjee, R. Savino, et al 2001. The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells. Int. J. Cancer 93: 674-680.
124. Naugler, W.E., T. Sakurai, S. Kim, et al 2007. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121-124.
125. Choy, H. & L. Milas 2003. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J. Natl. Cancer Inst. 95: 1440-1452.
126. Gasparini, G., R. Longo, R. Sarmiento & A. Morabito 2003. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 4: 605-615.
127. Baek, S.J. & T.E. Eling 2006. Changes in gene expression contribute to cancer prevention by COX inhibitors. Prog. Lipid Res. 45: 1-16.
128. Hiratsuka, S., K. Nakamura, S. Iwai, et al 2002. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2: 289-300.
129. Kaplan, R.N., R.D. Riba, S. Zacharoulis, et al 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827.
130. Pirinen, R., T. Leinonen, J. Bohm, et al 2005. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum. Pathol. 36: 44-50.
131. Ricciardelli, C., D.L. Russell, M.P. Ween, et al 2007. Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J. Biol. Chem. 282: 10814-10825.
132. Yee, A.J., M. Akens, B.L. Yang, et al 2007. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res. 9: R47.
133. Rahmani, M., B.W. Wong, L. Ang, et al 2006. Versican: signaling to transcriptional control pathways. Can. J. Physiol. Pharmacol. 84: 77-92.
134. Zheng, P.S., J. Wen, L.C. Ang, et al 2004. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J. 18: 754-756.
135. Schaefer, L., A. Babelova, E. Kiss, et al 2005. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 115: 2223-2233.
136. Brown, L.F., A.M. Dvorak & H.F. Dvorak 1989. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am. Rev. Respir. Dis. 140: 1104-1107.
137. Dvorak, H.F. 1986. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315: 1650-1659.
138. Massague, J., S.W. Blain & R.S. Lo 2000. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309.
139. Bierie, B. & H.L. Moses 2006. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6: 506-520.
140. Dumont, N. & C.L. Arteaga 2003. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 3: 531-536.
141. Yang, L., Y. Pang & H.L. Moses 2010. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31: 220-227.
142. Padua, D., X.H. Zhang, Q. Wang, et al 2008. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133: 66-77.
143. Alberti, C. 2008. Genetic and microenvironmental implications in prostate cancer progression and metastasis. Eur. Rev. Med. Pharmacol. Sci. 12: 167-175.
144. Yang, J., S.A. Mani, J.L. Donaher, et al 2004. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939.
145. Leptin, M. & B. Grunewald 1990. Cell shape changes during gastrulation in Drosophila. Development 110: 73-84.
146. Thisse, B., M. el Messal & F. Perrin-Schmitt 1987. The twist gene: isolation of a Drosophila zygotic gene necessary for the establishment of dorsoventral pattern. Nucleic Acids Res. 15: 3439-3453.
147. Chen, Z.F. & R.R. Behringer 1995. Twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes. Dev. 9: 686-699.
148. Soo, K., M.P. O'Rourke, P.L. Khoo, et al 2002. Twist function is required for the morphogenesis of the cephalic neural tube and the differentiation of the cranial neural crest cells in the mouse embryo. Dev. Biol. 247: 251-270.
149. Hay, E.D. 1995. An overview of epithelio-mesenchymal transformation. Acta. Anat. (Basel) 154: 8-20.
150. Pham, C.G., C. Bubici, F. Zazzeroni, et al 2007. Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs. Mol. Cell. Biol. 27: 3920-3935.
151. Steeg, P.S. 2003. Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer 3: 55-63.
152. Lockett, J., S. Yin, X. Li, et al 2006. Tumor suppressive maspin and epithelial homeostasis. J. Cell. Biochem. 97: 651-660.
153. Zou, Z., A. Anisowicz, M.J. Hendrix, et al 1994. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263: 526-529.
154. Huang, S.J., D. Hijnen, G.F. Murphy, et al 2009. Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J. Invest. Dermatol. 129: 2676-2685.
155. Tillman, D.K., Jr. & M.T. Carroll 2008. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J. Drugs. Dermatol. 7(1 Suppl 1): s7-s14.
156. Miller, R.L., J.F. Gerster, M.L. Owens, et al 1999. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol. 21: 1-14.
157. Harmey, J.H., C.D. Bucana, W. Lu, et al 2002. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int. J. Cancer 101: 415-422.
158. Pidgeon, G.P., J.H. Harmey, E. Kay, et al 1999. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br. J. Cancer 81: 1311-1317.
159. Taketomi, A., K. Takenaka, T. Matsumata, et al 1997. Circulating intercellular adhesion molecule-1 in patients with hepatocellular carcinoma before and after hepatic resection. Hepatogastroenterology 44: 477-483.
160. Wilson, J. & F. Balkwill 2002. The role of cytokines in the epithelial cancer microenvironment. Semin. Cancer Biol. 12: 113-120.
161. Song, K., Y. Chen, R. Goke, et al 2000. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191: 1095-1104.
162. Ashkenazi, A., R.C. Pai, S. Fong, et al 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104: 155-162.
163. Smyth, M.J., E. Cretney, K. Takeda, et al 2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193: 661-670.
164. Dranoff, G. 2004. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4: 11-22.
165. 1997. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J. Natl. Cancer Inst. 89: 1616-1620.
166. Fyfe, G., R.I. Fisher, S.A. Rosenberg, et al 1995. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13: 688-696.
167. Rosenberg, S.A., M.T. Lotze, J.C. Yang, et al 1993. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85: 622-632.
168. Mach, N. & G. Dranoff 2000. Cytokine-secreting tumor cell vaccines. Curr. Opin. Immunol. 12: 571-575.
169. Baron, J.A. & R.S. Sandler 2000. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu. Rev. Med. 51: 511-523.
170. Garcia-Rodriguez, L.A. & C. Huerta-Alvarez 2001. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 12: 88-93.
171. Elder, D.J., D.E. Halton, A. Hague & C. Paraskeva 1997. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer. Res. 3: 1679-1683.
172. Marx, J. 2004. Cancer research. Inflammation and cancer: the link grows stronger. Science 306: 966-968.